ProCE Banner Activity

Navigating Your Journey With CDK4/6 Inhibitors: A Guide for Thriving During Treatment

PDF

Download this resource for your patients with HR+/HER2- breast cancer considering or on CDK4/6 inhibitor therapy. Topics covered include factors to discuss when choosing therapy, potential side effects to expect and when to call your doctor, and simple strategies to help follow their prescribed therapy.

Released: March 24, 2025

Expiration: March 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP: consultant/advisor/speaker: Hologic, Stemline Therapeutics.

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.